Host CD15+ cells are required for engraftment promotion by anti-CD154 monoclonal antibody
| Recipient . | mAb . | No. chimeric (day 119) . | % Donor . |
|---|---|---|---|
| +/+ | hIgG | 0/10 | 0 |
| +/+ | Anti-CD154 | 7/10 | 26 ± 227-150 |
| CD154−/− | hIgG | 0/10 | 0 |
| CD154−/− | Anti-CD154 | 0/10 | 0 |
| Recipient . | mAb . | No. chimeric (day 119) . | % Donor . |
|---|---|---|---|
| +/+ | hIgG | 0/10 | 0 |
| +/+ | Anti-CD154 | 7/10 | 26 ± 227-150 |
| CD154−/− | hIgG | 0/10 | 0 |
| CD154−/− | Anti-CD154 | 0/10 | 0 |
B6 CD154+/+ (termed +/+) or CD154−/−mice were irradiated with 200 cGy TBI on day −1 and infused with 40 × 106 BALB/c BM on day 0. Irrelevant or anti-CD154 mAb was administered daily from day −1 through day +5 daily, then 2 ×/week until day 14 after BMT at 200 μg/dose. 10 mice/group received transplants. PBLs were typed for percentage donor-host at 6 weeks after BMT. No. chimeric indicates number of mice having >3% donor cells. Shown is average percentage donor ± 1 SD.
For abbreviations, see Table 1.
P < 0.001 as compared with hIgG-treated controls.